Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP)

Novartis reported that its anti‑BAFF‑R antibody ianalumab* met the primary endpoint in a Phase 3 trial in *primary immune thrombocytopenia (ITP), a rare autoimmune blood disorder that destroys platelets12.

In ITP patients previously treated with corticosteroids, ianalumab prolonged the duration of safe platelet levels during and after treatment*; the study’s primary endpoint was *time to treatment failure, which was significantly improved12.

A separate late‑stage study showed ianalumab + eltrombopag significantly improved time to treatment failure versus control in ITP1.

Patients on ianalumab also achieved a higher rate of sustained platelet count improvements, a key secondary endpoint1.

Novartis plans to present the ITP data at an upcoming medical meeting* and include them in *future regulatory submissions anticipated in 20271.

This ITP success follows top‑line results that both Phase 3 NEPTUNUS trials in Sjögren’s disease met their primary endpoints, underscoring consecutive late‑stage wins for ianalumab253.

Novartis’ newsroom confirms a dedicated press release on the ITP Phase 3 success* and an *ad hoc announcement on the Sjögren’s results on August 12, 20252.

Sources:

1. https://www.morningstar.com/news/dow-jones/20250812525/novartiss-ianalumab-meets-goals-in-phase-3-trials-to-treat-primary-immune-thrombocytopenia

2. https://www.novartis.com/news/newsroom

3. https://www.thepharmaletter.com/biotechnology/novartis-ianalumab-hits-goal-in-phase-iii-sjogrens-disease-trials

5. https://via.ritzau.dk/pressemeddelelse/14517829/novartis-pharma-ag?publisherId=90446&lang=en